madopar 100/25 benserazide hydrochloride / levodopa tablet bottle
roche products pty ltd - levodopa, quantity: 100 mg; benserazide hydrochloride, quantity: 28.5 mg (equivalent: benserazide, qty 25 mg) - tablet, uncoated - excipient ingredients: crospovidone; microcrystalline cellulose; colloidal anhydrous silica; pregelatinised maize starch; docusate sodium; iron oxide red; calcium hydrogen phosphate; magnesium stearate; ethylcellulose; mannitol - parkinson's disease and parkinsonian symptoms including post- encephalitic and toxic forms, but excluding drug induced parkinsonism.
madopar cr capsules
roche products ltd - benserazide hydrochloride; levodopa - modified-release capsule - 25mg ; 100mg
madopar 50mg/12.5mg capsules
roche products ltd - benserazide hydrochloride; levodopa - oral capsule - 12.5mg ; 50mg
madopar 200mg/50mg capsules
roche products ltd - benserazide hydrochloride; levodopa - oral capsule - 50mg ; 200mg
madopar 50mg/12.5mg dispersible tablets
roche products ltd - benserazide hydrochloride; levodopa - dispersible tablet - 12.5mg ; 50mg
madopar 100mg/25mg dispersible tablets
roche products ltd - benserazide hydrochloride; levodopa - dispersible tablet - 25mg ; 100mg
madopar
roche products (nz) ltd - benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base; levodopa 100mg; - capsule - 125 mg - active: benserazide hydrochloride 28.5mg equivalent to to 25 mg benserazide base levodopa 100mg excipient: gelatin indigo carmine iron oxide red magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.
madopar
roche products (nz) ltd - benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base; levodopa 200mg; - capsule - 250 mg - active: benserazide hydrochloride 57mg equivalent to to 50 mg benserazide base levodopa 200mg excipient: gelatin indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.
madopar
roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg; - capsule - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg excipient: gelatin indigo carmine iron oxide black magnesium stearate mannitol microcrystalline cellulose povidone purified talc titanium dioxide - madopar is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism.
madopar rapid 62.5
roche products (nz) ltd - benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base; levodopa 50mg; - dispersible tablet - 62.5 mg - active: benserazide hydrochloride 14.25mg equivalent to to 12.5 mg benserazide base levodopa 50mg excipient: citric acid magnesium stearate maize starch microcrystalline cellulose - madopar rapid is indicated for the treatment of all forms of parkinson's syndrome with the exception of medicine-induced parkinsonism. madopar rapid is a formulation which is suitable for patients with dysphagia (difficulties in swallowing) or who require a formulation with a more rapid onset of action, e.g. patients suffering from early morning and afternoon akinesia, or who exhibit "delayed on" or "wearing off" phenomena.